In clinical trials3,4Evidence: Smaller human trialsGut and digestion

Apraglutide3

Key takeaway

Apraglutide is a synthetic, long-acting analogue of glucagon-like peptide-2 (GLP-2), a gut hormone, recorded in FDA’s substance registry.3,4 It is being developed for short bowel syndrome with intestinal failure. In the randomized, placebo-controlled STARS trial of 163 patients, parenteral support volume fell by 25.5% with apraglutide and 12.5% with placebo after 24 weeks.4 No FDA approval is reported in the sources reviewed here, and apraglutide is not among the six peptides in HHS’s October 2026 draft enforcement-discretion policy.3,7

Apraglutide at a glance

What it isA synthetic 33-amino-acid GLP-2 analogue containing norleucine and a D-phenylalanine, according to FDA’s substance registry.3
FDA statusNot FDA-approved. None of the sources reviewed here reports an approval of apraglutide.3,4
Human evidenceOne randomized, double-blind, placebo-controlled Phase 3 trial (STARS) in 163 patients with short bowel syndrome, published in 2026.4
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is apraglutide?

Apraglutide is a synthetic peptide based on GLP-2, with substitutions including norleucine and a D-phenylalanine, according to FDA’s substance registry.3

How is apraglutide thought to work?

The STARS investigators describe it as a long-acting GLP-2 analogue that promotes intestinal adaptation, which may reduce dependence on parenteral support, nutrition and fluids that bypass the gut.4

What do human studies show?

STARS randomized 163 patients with short bowel syndrome and intestinal failure, 80 with a stoma and 83 with the colon still connected, to apraglutide or placebo.4

At 24 weeks, weekly parenteral support volume fell by 25.5% with apraglutide and 12.5% with placebo, and more patients cut at least one day a week of support (43.0% versus 27.5%). At 48 weeks in patients with the colon connected, the differences were not significant.4

ClinicalTrials.gov lists STARS (NCT04627025) as completed, and a further Phase 3 trial in short bowel syndrome with intestinal failure (NCT07742735) as recruiting in its August 4, 2026 record.1,2

What the evidence base contains

  • Controlled human trial STARS (NCT04627025): a global, randomized, double-blind, placebo-controlled Phase 3 trial in 163 patients with short bowel syndrome and intestinal failure (2026).4

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is apraglutide FDA-approved?

None of the sources reviewed here reports an approval of apraglutide by FDA.3,4

Apraglutide remains in clinical trials: a Phase 3 registration (NCT07742735) is listed as recruiting in its August 4, 2026 record.1

FDA’s compounding safety-risk page, current as of April 22, 2026, does not list apraglutide.5

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Apraglutide is not among them.6,7

Timeline

  1. The STARS Phase 3 trial of apraglutide in 163 patients is published.4

What is still unknown?

Whether it helps people whose colon is still connected over the longer term: at 48 weeks the differences from placebo in that group were not significant.4

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Apraglutide: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Apraglutide are a bounded selection, not every registration or paper about Apraglutide. For the years before Apraglutide was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Apraglutide as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Apraglutide in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 163 patients, apraglutide reduced parenteral support volume more than placebo at 24 weeks. Apraglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

Status sources checked through November 14, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Apraglutide?

In clinical trials; not FDA-approved. In a randomized, placebo-controlled Phase 3 trial of 163 patients, apraglutide reduced parenteral support volume more than placebo at 24 weeks. Apraglutide is not among the six peptides in HHS’s October 2026 draft policy.↗↗↗

The cited status sources were checked through November 14, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
1
Source years
3
Drugs@FDA applications
0

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected PubMed literature metadata records, regulatory records, and safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Apraglutide?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

8Selected dated records
13Connected citations
3Populated source years2024–2026
1/4Record lanes present

Registered human studies

Trial composition

8 of 8 selected trial records include at least one phase value; 8 of 8 include a status value in the retained structured contract.

PhasesPhase 1 4Phase 3 3Phase 2 1
Status at observationCompleted 6Active, not recruiting 1Recruiting 1

PubMed bibliography

Publication composition

0 of 0 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
0
FDA Federal Register documents
0
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
8

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 8 dated records

Research hub

Explore the Apraglutide evidence record

Open all 8 records →
8Dated records
1Evidence type
8Cited public sources
3Source years

Change ledger

Recently changed for Apraglutide

Open all 8 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT04627025

PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.

PeptideScanner change date
November 16, 2026
Cited source date
November 27, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04699032

PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.

PeptideScanner change date
November 16, 2026
Cited source date
October 26, 2024
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT04964986

PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide.

PeptideScanner change date
November 16, 2026
Cited source date
June 18, 2025
Evidence lane
Clinical trials

Official-source collections

Source records for Apraglutide

Open the full research atlas →
ClinicalTrials.gov8

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT07742735Registry update August 4, 2026 · current at observation
  2. NCT05706623Registry update July 10, 2025 · completed at observation
  3. NCT05018286Registry update July 2, 2025 · current at observation
Explore all selected trial records →Explore all public record history →

Evidence types

Coverage by source year

Selected records span October 24, 2024 to August 4, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. Food and Drug Administration3,5
  • U.S. Department of Health and Human Services6
Dated updates connected to this profile · 8

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT07742735↗

    PeptideScanner retained ClinicalTrials.gov record NCT07742735 at 2026-11-16T01:47:19.543Z. Its registry update date was 2026-08-04, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT05706623↗

    PeptideScanner retained ClinicalTrials.gov record NCT05706623 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-10, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT05018286↗

    PeptideScanner retained ClinicalTrials.gov record NCT05018286 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-07-02, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04964986↗

    PeptideScanner retained ClinicalTrials.gov record NCT04964986 at 2026-11-16T01:47:19.543Z. Its registry update date was 2025-06-18, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT04627025↗

    PeptideScanner retained ClinicalTrials.gov record NCT04627025 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-11-27, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT04699032↗

    PeptideScanner retained ClinicalTrials.gov record NCT04699032 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT06002555↗

    PeptideScanner retained ClinicalTrials.gov record NCT06002555 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-26, and PeptideScanner's reviewed identity mapping was apraglutide.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT05995704↗

    PeptideScanner retained ClinicalTrials.gov record NCT05995704 at 2026-11-16T01:47:19.543Z. Its registry update date was 2024-10-24, and PeptideScanner's reviewed identity mapping was apraglutide.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    ClinicalTrials.gov record NCT07742735 · retained source version 2026-08-04:4023f7314739caea80157c1523434645be32b32a965d3d0f20c7c1b5dcdb3218 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  2. 2
    ClinicalTrials.gov record NCT04627025 · retained source version 2024-11-27:33862c3edfc1d142d183d19484af2a0576a306288f110a84f44d6dec45422596 ↗

    ClinicalTrials.gov · Official source · Source checked November 16, 2026

  3. 3
    Apraglutide substance identity record ↗

    FDA Global Substance Registration System · Official source · Source checked November 15, 2026

  4. 4
    STARS Phase 3 Trial: Once-Weekly Apraglutide Reduces Parenteral Support in Short Bowel Syndrome-Intestinal Failure (2026) · PMID 42692160 ↗

    Clinical Gastroenterology and Hepatology · Official source · Source checked November 15, 2026

  5. 5
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  6. 6
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  7. 7
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026